XML 89 R78.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2024 | Mar. 31, 2023
Segment Reporting Information [Line Items] |  |
Net sales | $ 3,592 | $ 3,513
United States |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,659 | 1,667
International |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,933 | 1,846
BPS | Revision of Prior Period, Adjustment |  |
Segment Reporting Information [Line Items] |  |
Net sales |  | (2)
Other | Revision of Prior Period, Adjustment |  |
Segment Reporting Information [Line Items] |  |
Net sales |  | 2
Operating Segments | Medical Products and Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,229 | 1,157
Operating Segments | Healthcare Systems and Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 667 | 731
Operating Segments | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 578 | 523
Operating Segments | Kidney Care |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,102 | 1,072
Operating Segments | United States | Medical Products and Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 673 | 658
Operating Segments | United States | Healthcare Systems and Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 473 | 519
Operating Segments | United States | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 191 | 173
Operating Segments | United States | Kidney Care |  |
Segment Reporting Information [Line Items] |  |
Net sales | 311 | 293
Operating Segments | International | Medical Products and Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 556 | 499
Operating Segments | International | Healthcare Systems and Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 194 | 212
Operating Segments | International | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 387 | 350
Operating Segments | International | Kidney Care |  |
Segment Reporting Information [Line Items] |  |
Net sales | 791 | 779
Operating Segments | Infusion Therapies and Technologies | Medical Products and Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 966 | 911
Operating Segments | Infusion Therapies and Technologies | United States | Medical Products and Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 526 | 514
Operating Segments | Infusion Therapies and Technologies | International | Medical Products and Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 440 | 397
Operating Segments | Advanced Surgery | Medical Products and Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 263 | 246
Operating Segments | Advanced Surgery | United States | Medical Products and Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 147 | 144
Operating Segments | Advanced Surgery | International | Medical Products and Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 116 | 102
Operating Segments | Care and Connectivity Solutions | Healthcare Systems and Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 402 | 429
Operating Segments | Care and Connectivity Solutions | United States | Healthcare Systems and Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 278 | 298
Operating Segments | Care and Connectivity Solutions | International | Healthcare Systems and Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 124 | 131
Operating Segments | Front Line Care | Healthcare Systems and Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 265 | 302
Operating Segments | Front Line Care | United States | Healthcare Systems and Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 195 | 221
Operating Segments | Front Line Care | International | Healthcare Systems and Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 70 | 81
Operating Segments | Injectables and Anesthesia | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 328 | 305
Operating Segments | Injectables and Anesthesia | United States | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 191 | 173
Operating Segments | Injectables and Anesthesia | International | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 137 | 132
Operating Segments | Drug Compounding | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 250 | 218
Operating Segments | Drug Compounding | United States | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 0 | 0
Operating Segments | Drug Compounding | International | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 250 | 218
Operating Segments | Chronic Renal | Revision of Prior Period, Reclassification, Adjustment |  |
Segment Reporting Information [Line Items] |  |
Net sales |  | (8)
Operating Segments | Chronic Renal | Kidney Care |  |
Segment Reporting Information [Line Items] |  |
Net sales | 888 | 884
Operating Segments | Chronic Renal | United States | Kidney Care |  |
Segment Reporting Information [Line Items] |  |
Net sales | 226 | 229
Operating Segments | Chronic Renal | International | Kidney Care |  |
Segment Reporting Information [Line Items] |  |
Net sales | 662 | 655
Operating Segments | Acute Therapies | Revision of Prior Period, Reclassification, Adjustment |  |
Segment Reporting Information [Line Items] |  |
Net sales |  | 8
Operating Segments | Acute Therapies | Kidney Care |  |
Segment Reporting Information [Line Items] |  |
Net sales | 214 | 188
Operating Segments | Acute Therapies | United States | Kidney Care |  |
Segment Reporting Information [Line Items] |  |
Net sales | 85 | 64
Operating Segments | Acute Therapies | International | Kidney Care |  |
Segment Reporting Information [Line Items] |  |
Net sales | 129 | 124
Other |  |
Segment Reporting Information [Line Items] |  |
Net sales | 16 | 30
Other | United States |  |
Segment Reporting Information [Line Items] |  |
Net sales | 11 | 24
Other | International |  |
Segment Reporting Information [Line Items] |  |
Net sales | $ 5 | $ 6

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_BPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RestatementAxis=srt_RestatementAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_MedicalProductsAndTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_HealthcareSystemsAndTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_PharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_KidneyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_InfusionTherapiesAndTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_AdvancedSurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_CareAndConnectivitySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_FrontLineCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_InjectablesAndAnesthesiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_PharmaceuticalCompoundingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_ChronicRenalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_AcuteTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |